20 марта, 18:36

Pfizer's Xtandi Label Expansion Filing Gets Priority Review

FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

05 марта, 17:35

What's in Store for Catalyst (CPRX) This Earnings Season?

Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.

28 февраля, 17:06

4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio

Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.

27 февраля, 17:38

Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP

CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.

Выбор редакции
05 февраля, 22:24

Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses

Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.

30 января, 16:39

Charles Schwab, El Paso Energy, BP, Asahi Kasei and H Lundbeck A/S highlighted as Zacks Bull and Bear of the Day

Charles Schwab, El Paso Energy, BP, Asahi Kasei and H Lundbeck A/S highlighted as Zacks Bull and Bear of the Day

Выбор редакции
29 января, 16:45

Strength Seen in AbbVie (ABBV): Stock Soars 13.8%

AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.

16 января, 18:02

Teva's Trisenox Gets FDA Approval as First-Line Treatment

Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

20 декабря 2017, 22:21

Pfizer's Leukemia Drug Gets FDA Nod in First-Line Setting

Pfizer's (PFE) leukemia drug Bosulif receives FDA approval in first-line setting.

20 декабря 2017, 15:43

Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies

Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.

19 декабря 2017, 18:30

Pfizer Hikes Dividend, Announces $10B Share Buyback Plan

Pfizer (PFE) raises quarterly dividend for 2018 while also authorizing a new $10 billion share repurchase program.

12 декабря 2017, 17:21

Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

05 декабря 2017, 17:52

AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study

AbbVie (ABBV) announces data from a phase III study on risankizumab, which shows that a significant portion of plaque psoriasis patients treated with risankizumab achieved high levels of skin clearance.

29 ноября 2017, 19:11

Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study

Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.

Выбор редакции
06 ноября 2017, 18:33

What's in Store for Catalyst (CPRX) This Earnings Season?

Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

29 сентября 2017, 16:25

Ligand's Captisol Deals Set to Drive Growth in the Long Run

Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.

26 сентября 2017, 20:27

Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why

On Tuesday, shares of biopharmaceutical company Axovant Sciences Ltd. (AXON) have crashed, and the stock is currently down over 70% to $6.72 per share in late-morning trading after it said that its experimental Alzheimer's drug failed a key late-stage trial.

20 сентября 2017, 17:36

Teva/Nuvelution to Speed Up Development of Austedo in US

Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.